Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00321854
Status:
COMPLETED
Last Update Posted:
2014-05-16
First Post:
2006-05-03
Brief Title:
Study of Mirapex Pramipexole for the Early Treatment of Parkinsons Disease PD
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Parallel-group Clinical Trial to Examine the Efficacy and Safety of Early Pramipexole PPX Treatment Versus Delayed Pramipexole Treatment in Patients With New Onset Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2014-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a double blind placebo-controlled clinical trial of 15 months duration designed to examine early Mirapex pramipexole treatment vs delayed Mirapex pramipexole treatment in patients with new onset Parkinsons disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None